Overview: Human Leukocyte Antigen Cadaveric Crossmatch Panel
Introduction: The Human Leukocyte Antigen Cadaveric Crossmatch Panel is a diagnostic tool designed to assess transplant compatibility using whole blood samples. In India, deceased donor transplantation (~1,000â€"2,000 kidneys/year) requires pre-transplant crossmatch to detect donor-specific antibodies and prevent hyperacute rejection. High morbidity from under-performance in rural/low-SES transplant programs, limited crossmatch labs, delayed or incompatible allocation leading to graft loss. Per immunology practices aligned with ICMR and Indian Society of Organ Transplantation guidelines, the test employs immunoassay for HLA crossmatch and compatibility result over 1-2 days with high accuracy, valuable for real-time deceased donor matching. This diagnostic falls under transplant screening and targets recipients awaiting cadaveric organs, addressing accurate detection to guide safe transplantation. With elevated morbidity due to incompatibility risks, the test supports public health efforts by enabling precise compatibility assessment and improving graft survival. Its whole blood-based approach ensures reliable crossmatch.
Other Names: HLA Cadaver Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Cadaveric crossmatch standard; in India, used in NOTTO network.
Purpose: The test assesses 2 parameters including HLA crossmatch to guide transplant compatibility assessment, detect donor-specific antibodies, inform allocation.
Test Parameters: 1. HLA Crossmatch, 2. Compatibility Result.
Pretest Condition: No fasting required; patients should be on transplant waiting list.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for crossmatch).
Medical History: Patients should provide details on waiting list status, prior sensitization.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of incompatible transplant including rejection, benefits of crossmatch, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low cell viability can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Negative crossmatch indicates compatibility, necessitating specialist input.
Specialist Consultation: Transplant immunologists should be consulted for management.
Additional Supporting Tests: Virtual crossmatch, DSA for confirmation.
Test Limitations: Time-sensitive; comprehensive approach required.
References: Indian Journal of Transplantation 2024, Transplant Studies India 2023.
